{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRCA-Mutated+Ovarian+Carcinoma&page=2", "query": { "condition": "BRCA-Mutated Ovarian Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=BRCA-Mutated+Ovarian+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T07:53:36.667Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02950064", "title": "A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Neoplasms", "Ovarian Neoplasms", "Breast Neoplasms", "Prostatic Neoplasms" ], "interventions": [ { "name": "BTP-114", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Placon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2016-09", "completion_date": "2020-08", "has_results": false, "last_update_posted_date": "2019-01-14", "last_synced_at": "2026-05-22T07:53:36.667Z", "location_count": 8, "location_summary": "Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02950064" }, { "nct_id": "NCT02286687", "title": "Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Neoplasm", "ATM Gene Mutation", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Metastatic Malignant Neoplasm", "PALB2 Gene Mutation", "Recurrent Malignant Neoplasm", "Refractory Malignant Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2014-12-22", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-05-22T07:53:36.667Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02286687" }, { "nct_id": "NCT02392676", "title": "Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Platinum Sensitive Relapsed Ovarian Cancer" ], "interventions": [ { "name": "OLAPARIB", "type": "DRUG" }, { "name": "PLACEBO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "96 Years", "sex": "FEMALE", "summary": "18 Years to 96 Years · Female only" }, "enrollment_count": 0, "start_date": "2016-07", "completion_date": "2019-06", "has_results": false, "last_update_posted_date": "2016-05-02", "last_synced_at": "2026-05-22T07:53:36.667Z", "location_count": 15, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02392676" }, { "nct_id": "NCT05252390", "title": "NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Ovarian Cancer", "Ovary Cancer", "Cancer of Ovary", "Cancer of the Ovary", "Ovary Neoplasm", "Pancreatic Cancer", "Pancreas Cancer", "Cancer of Pancreas", "Cancer of the Pancreas", "Pancreas Neoplasm", "Prostate Cancer", "Prostatic Cancer", "Cancer of Prostate", "Cancer of the Prostate", "Prostate Neoplasm", "Castrate Resistant Prostate Cancer", "Castration Resistant Prostatic Cancer", "Castration Resistant Prostatic Neoplasms", "Triple-negative Breast Cancer", "Triple Negative Breast Cancer", "Triple Negative Breast Neoplasms", "Breast Cancer", "Breast Carcinoma", "Cancer of Breast", "Cancer of the Breast", "Breast Tumor" ], "interventions": [ { "name": "NUV-868", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2022-03-29", "completion_date": "2024-07-15", "has_results": false, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-05-22T07:53:36.667Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05252390" }, { "nct_id": "NCT01661868", "title": "Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2012-08", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2012-08-21", "last_synced_at": "2026-05-22T07:53:36.667Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01661868" }, { "nct_id": "NCT03740165", "title": "Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo for pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Placebo for olaparib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1367, "start_date": "2018-12-18", "completion_date": "2026-04-15", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-05-22T07:53:36.667Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Burbank, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03740165" }, { "nct_id": "NCT02282020", "title": "Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity" ], "interventions": [ { "name": "OLAPARIB", "type": "DRUG" }, { "name": "Single agent chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 266, "start_date": "2015-02-06", "completion_date": "2022-07-19", "has_results": true, "last_update_posted_date": "2022-07-26", "last_synced_at": "2026-05-22T07:53:36.667Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02282020" }, { "nct_id": "NCT01844986", "title": "Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Newly Diagnosed", "Advanced Ovarian Cancer", "FIGO Stage III-IV", "BRCA Mutation", "Complete Response", "Partial Response", "First Line Platinum Chemotherapy" ], "interventions": [ { "name": "Olaparib 300mg tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 450, "start_date": "2013-08-26", "completion_date": "2028-08-29", "has_results": true, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-05-22T07:53:36.667Z", "location_count": 81, "location_summary": "Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 63 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844986" }, { "nct_id": "NCT02889900", "title": "Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Platinum Resistant Ovarian Cancer" ], "interventions": [ { "name": "cediranib and olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 62, "start_date": "2017-01-17", "completion_date": "2021-03-16", "has_results": true, "last_update_posted_date": "2022-03-08", "last_synced_at": "2026-05-22T07:53:36.667Z", "location_count": 25, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Downey, California + 21 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Downey", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02889900" }, { "nct_id": "NCT00892736", "title": "Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Basal-Like Breast Carcinoma", "BRCA1 Mutation Carrier", "BRCA2 Mutation Carrier", "Breast Carcinoma", "Estrogen Receptor Negative", "HER2/Neu Negative", "Hereditary Breast and Ovarian Cancer Syndrome", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Progesterone Receptor Negative", "Prostate Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Solid Neoplasm", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 98, "start_date": "2009-04-20", "completion_date": "2017-05-19", "has_results": false, "last_update_posted_date": "2018-06-29", "last_synced_at": "2026-05-22T07:53:36.667Z", "location_count": 7, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00892736" } ] }